|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
640000560[A11602331]
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2015.09.01)(ÇöÀç¾à°¡)
\587 ¿ø/1Á¤(2014.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ãȲ»öÀÇ Å¸¿øÇü Çʸ§ÄÚÆÃ Á¤Á¦ÀÌ´Ù. [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
90T,150T
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 200¹Ð¸®±×·¥ |
150 Á¤ |
Foil |
8806400005605 |
8806400005629 |
|
| 200¹Ð¸®±×·¥ |
90 Á¤ |
Foil |
8806400005605 |
8806400005612 |
|
|
| ÁÖ¼ººÐÄÚµå |
127402ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
[À¯È¿±ÕÁ¾]
Æ÷µµ»ó±¸±Õ¼Ó, ¿¬¼â»ó±¸±Õ¼Ó(À屸±ÕÁ¦¿Ü), Æó·Å±¸±Õ, ÀÓ±Õ, ºê¶ó³ª¸á¶ó.īŻ¸®½º±Õ, ´ëÀå±Õ, ½ÃÆ®·Î¹ÚÅͼÓ, Ŭ·¹ºê½Ã¿¤¶ó¼Ó, ÇÁ·ÎÅ׿콺.¹Ì¶óºñ¸®½º, ÀÎÇ÷翣ÀÚ¼ÓÀÇ ¼¼Æ÷Ƽ¾Ï °¨¼º±Õ¿¡ ÀÇÇÑ Çϱ⠰¨¿°Áõ
[ÀûÀÀÁõ]
ÀÎÈĵο°, ±Þ¼º±â°üÁö ¿°,Æíµµ¿°,¸¸¼º±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ(°¨¿°½Ã), ¸¸¼ºÈ£Èí±â ÁúȯÀÇ 2Â÷°¨¿°, Æó·Å
½Å¿ì½Å¿°, ¹æ±¤¿°, ÀÓ±Õ¼º ¿äµµ¿°
¸ð³¶(Æ÷)¿°, ȳó¼ºÁÂâ, Àý, ÀýÁ¾Áõ, ¿Ë, ´Üµ¶, ºÀ¼Ò¿°, Àӯİü(Àý)¿°,Ç¥Àú, ȳ󼺼ÕÅéÁÖÀ§(µÑ·¹)¿°, ÇÇÇϳó¾ç, ÇѼ±¿°, °¨¿°¼ººÐ·ù, Ç×¹®ÁÖÀ§³ó¾ç
À¯¼±¿°, ¿Ü»ó.¼ö¼úâµîÀÇ Ç¥À缺 2Â÷°¨¿°
¾È°Ë¿°, ¸Æ¸³Á¾, ´©³¶¿°, °ËÆÇ¼±¿°, °¢¸·±Ë¾ç
ÁßÀÌ¿°, ºÎºñ°¿°
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Cefotiam]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:127402ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] - ÀÎÈĵο°, ±Þ¼º±â°üÁö¿°, Æíµµ¿°, Æó·Å, ½Å¿ì½Å¿°, ¹æ±¤¿°, ÀÓ±Õ¼º ¿äµµ¿°, ¸ð³¶(Æ÷)¿°, ³óÆ÷¼ºÁ â, Àý, ÀýÁ¾Áõ, ¿Ë, ´Üµ¶, ºÀ¼Ò¿°, Àӯİü(Àý)¿°, Ç¥Àú, ȳ󼺼ÕÅéÁÖÀ§(µÑ ·¹)¿°, ÇÇÇϳóâ, ÇѼ±¿°, °¨¿°¼ººÐ·ù, Ç×¹®ÁÖ³ó¾ç, À¯¼±¿°, ¿Ü»ó.¼ö¼úâ µîÀÇ Ç¥À缺2Â÷°¨¿°, ¾È°Ë¿°, ¸Æ¸³Á¾, ´©³¶¿°, °ËÆÇ¼±¿°, °¢¸·±Ë¾ç, ÁßÀÌ¿°, ºÎºñ°¿°ÀÇ °æ¿ì: Åë»ó, ¼ºÀÎÀÇ °æ¿ì ¿°»ê¼¼Æ÷Ƽ¾ÏÇí¼¼Æ¿·Î 1ÀÏ 300 -600mg(¿ª°¡)À» 3ȸ¿¡ ³ª´©¾î °æ±¸Åõ¿©ÇÑ´Ù.
- ¸¸¼º±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ(°¨¿°½Ã), ¸¸¼ºÈ£Èí±âÁúȯÀÇ 2Â÷ °¨¿°ÀÇ °æ¿ì: Åë»ó, ¼ºÀÎÀº ¿°»ê¼¼Æ÷Ƽ¾ÏÇí¼¼Æ¿·Î 1ÀÏ 600-1200mg(¿ª°¡)À» 3ȸ¿¡ ³ª´©¾î °æ±¸Åõ¿© ÇÑ´Ù. ´Ù¸¸, ¿¬·É ¹× Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨Çϰí ÁßÁõ ¶Ç´Â È¿°ú°¡ ºÒÃæºÐÇÏ´Ù°í »ý°¢µÉ °æ¿ì¿¡´Â 1ÀÏ 1200mg(¿ª°¡)À» 3ȸ¿¡ ³ª´©¾î °æ±¸Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
º»Á¦ÀÇ ¼ººÐ ¶Ç´Â ¿°»ê¼¼Æ÷Ƽ¾Ï¿¡ ÀÇÇÑ ¼ïÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
- º»Á¦ÀÇ ¼ººÐ ¶Ç´Â ¼¼Æè°è Ç×»ý¹°Áú¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ
- Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ
- º»ÀÎ ¶Ç´Â ¾çÄ£, ÇüÁ¦¿¡ ±â°üÁöõ½Ä, ¹ßÁø, ´ã¸¶Áø µîÀÇ ¾Ë·¹¸£±â Áõ»ó À» ³ªÅ¸³»±â ½¬¿î üÁúÀ» °¡Áø ȯÀÚ
- ÁßÁõÀÇ ½ÅÀåÇØ°¡ Àִ ȯÀÚ
- °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ (¾î·Á¿î)ȯÀÚ ¶Ç´Â ºñ°æ±¸ ¿µ¾ç½Ä ȯÀÚ, °í·ÉÀÚ, Àü½ÅÁõ»óÀÌ ³ª»Û ȯÀÚ(ºñŸ¹ÎK °áÇÌÁõ »óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÒ °Í)
|
| ÀÌ»ó¹ÝÀÀ |
- ¼ï:
µå¹°°Ô ¼ï Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí, ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, Çö¿î, º¯ÀÇ, À̸í, ¹ßÇÑ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÒ °Í.
°ú¹ÎÁõ: ¹ßÁø, ´ã¸¶Áø, È«¹Ý, ¼Ò¾ç, ¹ß¿, ¸²ÇÁ¼±Á¾¾ç, °üÀýÅë µîÀÇ °ú¹ÎÁõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÒ °Í.
½ÅÀå: ¶§·Î BUN»ó½Â, ¶Ç´Â µå¹°°Ô Å©·¹¾ÆÆ¼´Ñ »ó½Â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¿°»ê¼¼Æ÷Ƽ¾Ï¿¡¼ µå¹°°Ô ±Þ¼º½ÅºÎÀü µîÀÇ ÁßÁõÀÇ ½ÅÀåÇØ°¡ ³ªÅ¸ ³¯ ¼ö ÀÖ´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ÃæºÐÇÑ °üÂûÀ» ÇàÇÑ´Ù. ÀÌ»óÀÌ È®À뵃 °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÒ °Í.
Ç÷¾×: ¶§·Î ºóÇ÷, È£»ê±¸Áõ´Ù, µå¹°°Ô °ú¸³±¸ °¨¼Ò, Ç÷¼ÒÆÇ °¨¼Ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¿°»ê¼¼Æ÷Ƽ¾Ï¿¡¼ µå¹°°Ô ¿ëÇ÷¼ººóÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù´Â º¸°í°¡ ÀÖ´Ù.
°£Àå: ¶§·Î GOT, GPT, r-GTP, AL-PÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ: µå¹°°Ô À§¸·¼º ´ëÀå¿° µîÀÇ Ç÷º¯À» ¼ö¹ÝÇÑ ÁßÁõÀÇ ´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ¿©·¯ Ƚ¼öÀÇ Çϸ®°¡ ÀϾ´Â °æ¿ì¿¡´Â Áï°¢ Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÒ °Í. ¶§¶§·Î Çϸ®, º¹Åë, ¿À½É, ±¸Åä, º¯ºñ µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
È£Èí±â: µå¹°°Ô ¹ß¿, ÇØ¼Ò, È£Èí°ï¶õ, ÈäºÎ X¼±ÀÌ»ó, È£»ê±¸Áõ´Ù µîÀ» ¼ö¹ÝÇÏ´Â °£Áú¼ºÆó¿°, PIE ÁõÈıº µîÀÌ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î ±×·± Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ºÎ½ÅÇÇÁúÈ£¸£¸óÁ¦ÀÇ Åõ¿© µîÀÇ ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÒ °Í
±Õ±³´ëÁõ: µå¹°°Ô ±¸³»¿°, ĵð´ÙÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ºñŸ¹Î°áÇÌÁõ: µå¹°°Ô ºñŸ¹Î K°áÇÌÁõ »ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâ µî) ºñŸ¹Î B±º °áÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿° µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ: ¶§·Î Çö¿î, ¸¶ºñ(Àú¸²), ÈäÅëÀÌ ÀϾ ¼ö ÀÖ´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ÁÖ¼ººÐÄÚµå |
127402ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| ´ëÇ¥ÄÚµå |
8806400005605 |
| BIT ¾àÈ¿ºÐ·ù |
2¼¼´ë ¼¼ÆÈ·Î½ºÆ÷¸°°è (Cephalosporins; Second Generation)
|
| º¹ÁöºÎºÐ·ùÄÚµå |
618 (ÁÖ·Î ±×¶÷¾ç¼º, À½¼º±Õ¿¡ ÀÛ¿ëÇÏ´Â °Í )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
ºê·Î½ºÆ÷¸°Á¤200¹Ð¸®±×¶÷(¿°»ê¼¼Æ÷Ƽ¾ÏÇí¼¼Æ¿)/ A11602331
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 90/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199201349 /´ëÇ¥ÄÚµå: 8806400005605/Ç¥ÁØÄÚµå: 8806400005612
±¸¹ÙÄÚµå: -/ºñ°í:-
ºê·Î½ºÆ÷¸°Á¤200¹Ð¸®±×¶÷(¿°»ê¼¼Æ÷Ƽ¾ÏÇí¼¼Æ¿)/ A11602331
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 150/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 199201349 /´ëÇ¥ÄÚµå: 8806400005605/Ç¥ÁØÄÚµå: 8806400005629
±¸¹ÙÄÚµå: 8801007603261/ºñ°í:-
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefotiam¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
|
| Pharmacology |
Cefotiam¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotiam works by inhibiting bacterial cell wall biosynthesis.
|
| Metabolism |
Cefotiam¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Cefotiam¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 40%
|
| Half-life |
Cefotiam¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Approximately 1 hour.
|
| Absorption |
Cefotiam¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection.
|
| Pharmacokinetics |
Cefotiam hexetyl HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- »ýü³»ÀÌ¿ë·ü : ±ÙÀ°ÁÖ»ç : 0.5 g Åõ¿©½Ã 60%, 1 g Åõ¿©½Ã 86%
- ºÐÆ÷ :
- ºÐÆ÷¿ëÀû : 0.5 L/kg
- ´ãÁó, °ñ¼ö, »óóºÎÀ§ÀÇ Ã¼¾×¿¡ °í³óµµ·Î ºÐÆ÷
- ÅÂ¹Ý Åë°ú
- ´Ü¹é°áÇÕ : 40-62%
- ¹Ý°¨±â :
- Á¤»ó ½Å±â´É : 0.6-1.5 ½Ã°£ (¿ë·® ÀÇÁ¸Àû)
- ½ÉÇÑ ½ÅÀå¾Ö ȯÀÚ (CLcr 3-10 mL/min) : 5.3 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : Cefotiam hydrochloride
- ±ÙÀ°ÁÖ»ç : ¾à 45ºÐ
- Á¤¸ÆÁÖ»ç : 15ºÐ
- ¼Ò½Ç : 50-67%´Â ¹Ìº¯Èü·Î¼ ½Å¹è¼³µÇ¸ç, 0.2% Á¤µµ¸¸ÀÌ ´ãÁóÀ¸·Î ¹è¼³µÈ´Ù.
|
| Biotransformation |
Cefotiam¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Cefotiam¿¡ ´ëÇÑ Toxicity Á¤º¸ Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
|
| Drug Interactions |
Cefotiam¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefotiam¿¡ ´ëÇÑ Description Á¤º¸ One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms. [PubChem]
|
| Dosage Form |
Cefotiam¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Not Available
|
| Drug Category |
Cefotiam¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial Agents
|
| Smiles String Canonical |
Cefotiam¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCN1N=NN=C1SCC1=C(N2C(SC1)C(NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
|
| Smiles String Isomeric |
Cefotiam¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
|
| InChI Identifier |
Cefotiam¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1/f/h21,30H,19H2
|
| Chemical IUPAC Name |
Cefotiam¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|